Your drug plan sent a notice, maybe two. You filed them with the rest of the November mail and kept the same Part D plan you've had since 2019. If you do that for 2027, you are signing up for a premium increase that averages 50% — from $34 a month to a projected $51 — according to KFF's analysis of Medicare Part D premiums and cost sharing in 2027.
That is the sticker price. The deeper problem is that three separate things change on January 1 every year, and none of them is your decision: the formulary (the plan's official list of covered drugs), the tier (the pricing bucket each drug sits in), and the pharmacy network (which counters charge you the preferred rate). A drug you've taken for a decade can move to a higher tier without a single change to your health.
I'm Matthew Wood, an insurance advisor at Core Benefits in Clayton, North Carolina. Most of the plan reviews I run in the fall aren't for people who just got diagnosed with something new. They're for people whose coverage quietly shifted underneath them.
What is plan "creep," and why does it cost you money?
Plan creep is the annual drift of a drug plan's formulary, tiers, and pharmacy network — the three levers that set what you pay — without any change on your end. You keep the same card and the same member ID. The plan behind it repositions your medications and reprices your refills.
Three levers move, and each one bites differently. A formulary is the plan's covered-drug list; if your medication drops off it, you can request an exception or pay full price. A tier is the cost-sharing bucket a drug sits in, so moving from tier 2 to tier 3 can multiply your copay while the drug stays "covered." A pharmacy network splits into preferred and standard counters, and the same bottle of pills can cost one copay at a preferred pharmacy and a higher one a mile down the road.
Plans are not required to make any of those moves loud. CMS does review plan benefit designs and formulary structures each year and flags cost sharing that exceeds its tier thresholds (CMS 2027 Part D bidding instructions). What the agency reviews, though, is whether a design is permissible — not whether it is cheaper for you specifically.
The premium side shows the same pattern. For 2027, the average beneficiary has 9 stand-alone Part D plans to choose from, down from 11 in 2026, and no zero-premium PDP is available to enrollees who don't receive a low-income subsidy (KFF's 2027 plan landscape analysis). The plans still offering low premiums are not necessarily the plans covering your drugs.
Does the $2,000 out-of-pocket cap make shopping unnecessary?
No. The cap limits what you can spend on covered drugs in a year, but it does not set your premium, your copays before you reach it, or the tier your drug sits in. A plan can keep you under the cap and still cost you hundreds more than the plan next door.
The cap itself is one piece of the Inflation Reduction Act's Part D redesign. CMS is now codifying that redesign for 2027 and beyond, including eliminating the coverage gap phase, establishing a reduced annual out-of-pocket threshold, removing cost sharing in the catastrophic phase, and folding in the Manufacturer Discount Program that replaced the Coverage Gap Discount Program on January 1, 2025 (CMS Contract Year 2027 Part D final rule).
What that means in plain terms: the old "donut hole" — the coverage gap where you paid a larger share — is going away as a distinct phase. Once you pass the out-of-pocket threshold, cost sharing in the catastrophic phase disappears entirely. That is real protection for anyone on expensive brand-name drugs.
Here is the catch. The cap protects your worst year, not your typical one. Most people with a handful of generic maintenance medications never come close to the threshold — they live entirely in the copay tiers, where the plan's formulary decisions decide the bill. And because plan sponsors now carry a larger share of costs above the cap, they have every reason to manage the rest of the benefit tightly. KFF notes that the redesign shifted costs under the drug benefit toward sponsors, with those costs potentially passed to beneficiaries through premiums (KFF on Part D rebates).
Treat the cap as a backstop. It is not a reason to skip the comparison.
Does the pharmacy counter change what you pay?
Yes — sometimes more than the plan itself. Every Part D plan negotiates separate rates with pharmacies and designates some as preferred. Fill the same prescription at a preferred counter and you pay the lower copay; fill it at a standard one and you pay more, with the same card and the same plan.
This is where a lot of Johnston County beneficiaries lose money without noticing. The pharmacy nearest the house is convenient, and convenience is exactly what the plan's network design is betting on. A plan that looks cheap on paper can be the more expensive choice if it treats your regular pharmacy as a standard (non-preferred) counter.
The fix costs nothing: pull each candidate plan's pharmacy directory and confirm your actual pharmacy — the one you drive to, not a chain's flagship listing — appears as preferred. Then check mail order. Many plans price a 90-day mail-order supply below three retail copays, which matters for anyone on a stable monthly medication.
One more network wrinkle worth knowing: CMS finalized a new special enrollment period that lets Medicare Advantage enrollees change plans when a provider leaves their network (CMS Contract Year 2027 final rule). That protection exists precisely because networks shift mid-year. Treat your pharmacy the same way you treat your doctor — verify it before you commit.
How do you actually audit your drug plan before December 7?
Take a paper inventory of every prescription you fill, then price that exact list against every plan available in your ZIP code. Not the plan with the lowest premium — the plan with the lowest total for your drugs, at your pharmacy, for a full year.
The order matters, because a low premium is the easiest number to fall for and the least informative. Medicare's Plan Finder prices a drug list across plans, and the resulting annual estimate already bundles premium, deductible, and copays. Work from that total.
What you compare | Why it decides your bill |
|---|---|
The formulary entry for each drug | A drug that isn't covered means an exception request or full retail price, which no premium saving offsets |
The tier each drug sits in | A one-tier move can raise a monthly copay several times over while the drug stays "covered" |
Your pharmacy's network status | Preferred versus standard pricing changes the same fill with no change to your plan |
The monthly premium | Sets your fixed cost regardless of whether you fill a single prescription |
The deductible | Plans can apply a deductible to some tiers and not others, so a low premium can hide a higher first-fill cost |
Two habits make this fast. First, log into your Medicare account and pull your current plan's drug list rather than reconstructing it from memory — the claim history is more accurate than anyone's recall. Second, run the comparison before the deadline, not on December 6. Open enrollment for 2027 coverage closes December 7, and the plans you compare are the ones that will exist on January 1.
Then write down what you chose and why. Next October, that note becomes the baseline for the following year's review — and it will tell you, in your own handwriting, whether the plan moved or you did.
What does skipping the comparison actually cost?
It costs the difference between your current plan and the best-fit plan, multiplied by twelve months — and for a meaningful share of enrollees in 2027, that gap is large. KFF estimates that nearly 30% of stand-alone PDP enrollees without a low-income subsidy (3.9 million people) will pay at least $100 a month in 2027 if they keep their current plan, while more than half will pay under $20 (KFF, October 2026).
Read that range again. Two neighbors, same county, same Medicare card, same handful of generics — one pays $20 a month and one pays $100 or more. The difference isn't income or health. It's whether they opened the envelope.
The same analysis puts the average premium for drug coverage inside a Medicare Advantage prescription drug plan at about $9 a month, against $51 for a stand-alone plan. That gap is structural: MA-PD sponsors can use rebate dollars to reduce Part D premiums in a way stand-alone sponsors cannot. It doesn't automatically make an MA-PD the better buy for you — your doctors, your pharmacy, and your travel habits all belong in that decision — but it is a comparison most people never run.
Here is the framing I give clients in Clayton. You don't shop your drug plan to find a bargain. You shop it to find out what changed while you weren't looking. Sometimes the answer is nothing, and you keep your plan with confidence. Sometimes the answer is a $50 monthly premium increase and a tier shift on your blood thinner — and you have until December 7 to do something about it.
The cost of looking is an hour with a drug list and a laptop. The cost of not looking is a year of bills you didn't choose.
Bring three things to any plan review: your full medication list with dosages, the name of the pharmacy you actually use, and your current plan's Annual Notice of Change. Those three documents settle most of the comparison before anyone opens a laptop.
Matthew Wood is an insurance advisor at Core Benefits in Clayton, North Carolina, where he reviews Medicare Advantage and Part D coverage for clients across Johnston County and the greater Raleigh area. He is not connected with the federal Medicare program, and plan availability, premiums, and formularies vary by ZIP code. Verify any plan's current details at Medicare.gov or with the plan directly before enrolling.
No comments yet. Be the first to share your thoughts!